BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9580385)

  • 1. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
    Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
    J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
    Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
    J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
    Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
    J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
    Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
    J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
    J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
    Enschede SH; Porter C; Venugopal P; Gregory SA
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
    Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
    Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
    Smalley RV; Weller E; Hawkins MJ; Oken MM; O'Connell MJ; Haase-Statz S; Borden EC
    Leukemia; 2001 Jul; 15(7):1118-22. PubMed ID: 11455982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
    Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
    J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival.
    Aviles A; Duque G; Talavera A; Guzman R
    Leuk Lymphoma; 1996 Feb; 20(5-6):495-9. PubMed ID: 8833409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
    Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
    Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
    Smalley RV; Andersen JW; Hawkins MJ; Bhide V; O'Connell MJ; Oken MM; Borden EC
    N Engl J Med; 1992 Nov; 327(19):1336-41. PubMed ID: 1406835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
    [No Abstract]   [Full Text] [Related]  

  • 17. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
    Enschede SH; Shahidi H; Venugopal P; Riley MB; Huang R; Jajeh A; Preisler HD; Gregory SA
    Leuk Lymphoma; 2001 Jan; 40(3-4):325-34. PubMed ID: 11426554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
    Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
    Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.